Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635889 · ClinicalTrials.gov registry record · Phase 2
Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain
A Phase 2 study of Nephrolithiasis, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT06635889 is a Phase 2 study of Nephrolithiasis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 116 participants, roughly in line with the 117-participant average among 16 other Nephrolithiasis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06635889, a Phase 2 study of Nephrolithiasis, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy. This is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.
Conditions Studied
Interventions
- DRUG Bupivacaine
- OTHER Normal saline
Study Locations (1)
Illinois
- The University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06635889
The ClinicalTrials.gov registry entry for NCT06635889 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 117-participant average among 16 other Nephrolithiasis trials with a reported enrollment target. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nephrolithiasis appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine is the first listed.
NCT06635889 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06635889 about?
NCT06635889 is a clinical study titled "Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain". Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the e...
What is the current status of trial NCT06635889?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2025-03-26. Estimated completion is 2029-10.
What conditions does trial NCT06635889 study?
This clinical trial studies the following conditions: Nephrolithiasis.
What interventions are being tested in trial NCT06635889?
The interventions under investigation include: Bupivacaine (DRUG), Normal saline (OTHER).
Who is sponsoring clinical trial NCT06635889?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635889 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nephrolithiasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease
RECRUITING · NA
-
Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)
RECRUITING · NA
-
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
RECRUITING · NA
-
Gut Oxalate Absorption in Calcium Oxalate Stone Disease
RECRUITING · NA
-
Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.
RECRUITING
-
Evaluation of Genetic Abnormalities Amongst Calcium Phosphate Stone Formers
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.